BRPI1007161A2 - composição farmacêutica oral, e processo para preparar uma composição - Google Patents
composição farmacêutica oral, e processo para preparar uma composiçãoInfo
- Publication number
- BRPI1007161A2 BRPI1007161A2 BRPI1007161A BRPI1007161A BRPI1007161A2 BR PI1007161 A2 BRPI1007161 A2 BR PI1007161A2 BR PI1007161 A BRPI1007161 A BR PI1007161A BR PI1007161 A BRPI1007161 A BR PI1007161A BR PI1007161 A2 BRPI1007161 A2 BR PI1007161A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- preparing
- oral pharmaceutical
- pharmaceutical composition
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09100083 | 2009-01-29 | ||
| EP09100083.6 | 2009-01-29 | ||
| PCT/EP2010/050892 WO2010094535A1 (en) | 2009-01-29 | 2010-01-27 | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1007161A2 true BRPI1007161A2 (pt) | 2016-02-23 |
| BRPI1007161B1 BRPI1007161B1 (pt) | 2022-03-22 |
Family
ID=40622206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007161-0A BRPI1007161B1 (pt) | 2009-01-29 | 2010-01-27 | Composição farmacêutica oral sólida, e, processo para preparar uma composição |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20120108464A1 (pt) |
| EP (1) | EP2391349B1 (pt) |
| JP (1) | JP5576401B2 (pt) |
| KR (1) | KR101640164B1 (pt) |
| CN (2) | CN104083328B (pt) |
| AU (1) | AU2010215646B2 (pt) |
| BR (1) | BRPI1007161B1 (pt) |
| CA (1) | CA2747395C (pt) |
| CY (1) | CY1115673T1 (pt) |
| DK (1) | DK2391349T3 (pt) |
| EA (1) | EA022057B1 (pt) |
| ES (1) | ES2511047T3 (pt) |
| HR (1) | HRP20141006T1 (pt) |
| IL (1) | IL213545A (pt) |
| ME (1) | ME01927B (pt) |
| MX (1) | MX2011007267A (pt) |
| PL (1) | PL2391349T3 (pt) |
| PT (1) | PT2391349E (pt) |
| RS (1) | RS53554B1 (pt) |
| SI (1) | SI2391349T1 (pt) |
| SM (1) | SMT201400155B (pt) |
| WO (1) | WO2010094535A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2520990T3 (es) * | 2009-01-29 | 2014-11-12 | Ucb Pharma, S.A. | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina |
| CN104800176A (zh) * | 2015-04-23 | 2015-07-29 | 广东赛烽医药科技有限公司 | 一种布瓦西坦口崩片及其制备方法 |
| JP6902033B2 (ja) | 2015-12-30 | 2021-07-14 | アダマス ファーマシューティカルズ， インコーポレイテッド | 発作−関連障害の処置のための方法および組成物 |
| US20190125725A1 (en) * | 2016-05-12 | 2019-05-02 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
| EA202090461A1 (ru) | 2017-08-18 | 2020-06-29 | Эббви Инк. | Фармацевтические препараты для лечения эндометриоза, миомы матки, синдрома поликистоза яичников или аденомиоза |
| US12083227B2 (en) * | 2017-08-18 | 2024-09-10 | Abbvie Inc. | Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
| CN109833300A (zh) * | 2017-11-28 | 2019-06-04 | 浙江京新药业股份有限公司 | 一种抗癫痫药物口服组合物及其制备方法 |
| CN112261942A (zh) | 2018-04-19 | 2021-01-22 | 艾伯维公司 | 治疗重度月经出血的方法 |
| CN110638743B (zh) * | 2019-10-25 | 2023-03-28 | 乐普制药科技有限公司 | 一种含布立西坦的组合物 |
| CN113288872A (zh) * | 2020-02-21 | 2021-08-24 | 广东东阳光药业有限公司 | 一种2-吡咯烷酮衍生物的组合物及其制备方法 |
| CN112933059A (zh) * | 2021-03-25 | 2021-06-11 | 浙江昂利康制药股份有限公司 | 一种布立西坦片剂的干法制粒工艺 |
| CN115192572B (zh) * | 2021-04-08 | 2023-09-19 | 成都同道慧宜生物医药科技有限公司 | 布立西坦药剂、其制备方法和应用 |
| CN115721624A (zh) * | 2021-08-25 | 2023-03-03 | 北京海美源医药科技有限公司 | 一种布立西坦药物组合物及其制备方法和其应用 |
| EP4431086A1 (en) | 2023-03-16 | 2024-09-18 | Adalvo Limited | Pharmaceutical composition comprising (2s)-2-[(4r)-2-oxo-4-propyltetrahydro-1h-pyrrol-1-yl]butanamide |
| EP4491177A1 (en) | 2023-07-14 | 2025-01-15 | Sanovel Ilac Sanayi ve Ticaret A.S. | Film coated tablets of brivaracetam |
| EP4491176A1 (en) | 2023-07-14 | 2025-01-15 | Sanovel Ilac Sanayi ve Ticaret A.S. | A film coated tablet comprising brivaracetam |
| EP4527378A1 (en) | 2023-09-22 | 2025-03-26 | Sanovel Ilac Sanayi ve Ticaret A.S. | A film coated tablet of brivaracetam |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
| KR100568380B1 (ko) * | 2001-05-01 | 2006-04-05 | 화이자 프로덕츠 인코포레이티드 | 저 투약량 약학 조성물의 제조 방법 |
| JP2005298338A (ja) | 2002-02-27 | 2005-10-27 | Eisai Co Ltd | 速崩壊性圧縮成形製剤 |
| CN1186094C (zh) * | 2002-07-01 | 2005-01-26 | 蔡海德 | 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法 |
| WO2006099005A1 (en) * | 2005-03-09 | 2006-09-21 | Trustees Of Dartmouth College | Method for identifying agents which modulate gtpase activity involved in insulin-stimulated glut4 translocation |
| EP1731149A1 (en) * | 2005-06-08 | 2006-12-13 | Ucb S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy |
| TW200738280A (en) * | 2005-07-26 | 2007-10-16 | Ucb Sa | Novel pharmaceutical compositions comprising levetiracetam and process for their preparation |
| EP2041084B1 (en) * | 2006-06-08 | 2013-11-06 | UCB Pharma, S.A. | Co-crystals of pyrrolidinones |
| EP2056792B1 (en) * | 2006-08-31 | 2023-06-07 | Adare Pharmaceuticals, Inc. | Drug delivery systems comprising solid solutions of weakly basic drugs |
| US20080280862A1 (en) * | 2007-01-05 | 2008-11-13 | Cermak Jennifer M | Methods, compositions, and kits for the treatment of pain |
| ES2520990T3 (es) * | 2009-01-29 | 2014-11-12 | Ucb Pharma, S.A. | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina |
-
2010
- 2010-01-27 KR KR1020117019926A patent/KR101640164B1/ko active Active
- 2010-01-27 CN CN201410370728.3A patent/CN104083328B/zh active Active
- 2010-01-27 WO PCT/EP2010/050892 patent/WO2010094535A1/en not_active Ceased
- 2010-01-27 US US13/142,869 patent/US20120108464A1/en not_active Abandoned
- 2010-01-27 EP EP10701245.2A patent/EP2391349B1/en active Active
- 2010-01-27 PT PT107012452T patent/PT2391349E/pt unknown
- 2010-01-27 EA EA201101116A patent/EA022057B1/ru unknown
- 2010-01-27 CA CA2747395A patent/CA2747395C/en active Active
- 2010-01-27 RS RSP20140539 patent/RS53554B1/sr unknown
- 2010-01-27 CN CN201080005399.2A patent/CN102292071B/zh active Active
- 2010-01-27 HR HRP20141006AT patent/HRP20141006T1/hr unknown
- 2010-01-27 PL PL10701245T patent/PL2391349T3/pl unknown
- 2010-01-27 US US13/146,074 patent/US10729653B2/en active Active
- 2010-01-27 ME MEP-2014-124A patent/ME01927B/me unknown
- 2010-01-27 ES ES10701245.2T patent/ES2511047T3/es active Active
- 2010-01-27 MX MX2011007267A patent/MX2011007267A/es active IP Right Grant
- 2010-01-27 AU AU2010215646A patent/AU2010215646B2/en active Active
- 2010-01-27 JP JP2011546825A patent/JP5576401B2/ja active Active
- 2010-01-27 DK DK10701245.2T patent/DK2391349T3/da active
- 2010-01-27 SI SI201030776T patent/SI2391349T1/sl unknown
- 2010-01-27 BR BRPI1007161-0A patent/BRPI1007161B1/pt active IP Right Grant
-
2011
- 2011-06-14 IL IL213545A patent/IL213545A/en active IP Right Grant
-
2014
- 2014-10-23 CY CY20141100876T patent/CY1115673T1/el unknown
- 2014-10-23 SM SM201400155T patent/SMT201400155B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1007161A2 (pt) | composição farmacêutica oral, e processo para preparar uma composição | |
| BRPI1011764A2 (pt) | composição farmacêutica, e, método para preparar uma composição farmacêutica | |
| BRPI0905717A2 (pt) | Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica | |
| BR112012002102A2 (pt) | composição farmaceutica e metodo para preparar uma composição farmaceutica | |
| BRPI0912384A2 (pt) | composição, e, método para preparar uma composição | |
| BRPI1007211A2 (pt) | composição farmacêutica oral em uma forma sólida, e, processo para preparar uma composição. | |
| BRPI0908092A2 (pt) | Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante | |
| BRPI0909691A8 (pt) | composto, método para preparar um composto, e, composição farmacêutica | |
| BR112012009609A2 (pt) | método para fabricar uma dispersão sólida, dispersão sólida , preparação farmacêutica e composições | |
| BR112012030590A2 (pt) | composição não aquosa para cuidados orais e processo para a preparação de uma composição não aquosa para cuidados orais | |
| BRPI0924136A2 (pt) | composição farmacêutica sólida compreendendo amlodipina e losartan e processo para a produção da mesma | |
| BR112014015042A2 (pt) | composição farmacêutica, e, método para obter uma composição radiofarmacêutica | |
| BR112013008008A2 (pt) | composto, composição farmacêutica e processo para preparar um composto | |
| BR112012031033A2 (pt) | composição de si--g-poliolefina e processo para fazer uma composição de si-g-poliolefina | |
| BRPI1016132A2 (pt) | composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável. | |
| BRPI1013561A2 (pt) | Processo para a preparação de alogliptina | |
| BRPI1008598A2 (pt) | composição farmacêutica para inalação | |
| BR112012004864A2 (pt) | composição particulada , processo para produzir uma composição particulada, e , material pulverulento | |
| BRPI0910545A2 (pt) | processo contínuo para fazer composições farmacêuticas | |
| BR112012015100A2 (pt) | composição de polímero modificado, artigo e método para produzir uma composição de polímero modificado | |
| BRPI0814821A2 (pt) | Composto, composição farmacêutica, e, processo para preparar um composto | |
| BRPI1007484A2 (pt) | composição farmacêutica para administração oral | |
| BRPI0925100A2 (pt) | forma de dosagem osmótica e processo para preparar uma forma de dosagem osmótica | |
| BRPI1010707A2 (pt) | composição farmacêutica, processo para o preparo da mesma, processo para o preparo de uma formulação injetável e formulação injetável | |
| BRPI1007654A2 (pt) | composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: UCB BIOPHARMA SPRL (BE) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: UCB BIOPHARMA SRL (BE) |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |